Status
Conditions
Treatments
About
The purpose of the study is to assess the impact of HeartLogic-guided management on clinical outcomes among patients implanted with an eligible cardiac device.
Full description
The study is a pragmatic, registry-based, randomized controlled trial. Eligible patients in Denmark will be randomized 1:1 to either HeartLogic-guided management or usual care. During the trial, patients in the HeartLogic arm will be contacted by the study team in case of any HeartLogic alerts for evaluation and treatment decisions. There will be no mandatory in-person visits scheduled in the trial. HeartLogic alerts will be managed according to a prespecified management guide. Trial data besides device-related data will be retrieved from the Danish nationwide health registries including baseline information and endpoint data. The control group will receive usual HF care in the Danish health system without the involvement of the study team. The study will comply with the standards of the CONSORT statement and the principles of the Declaration of Helsinki.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
There are no specific exclusion criteria for the trial.
Primary purpose
Allocation
Interventional model
Masking
1,428 participants in 2 patient groups
Loading...
Central trial contact
Marie Terese Barlebo Madsen, PhD; Niklas Dyrby Johansen, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal